Page 68 - 84_02

83 Darwish OM, Raj G V. Management of biochemical
recurrence after primary localized therapy for prostate
cancer. Front Oncol 2012; 2: 1–6.
84 Grossmann M, Zajac JD. Androgen deprivation
therapy in men with prostate cancer: how should the
side effects be monitored and treated? Clin Endocrinol
2011; 74: 289–93.
85 Czifra G, Varga A, Nyeste K, et al. Increased
expressions of cannabinoid receptor-1 and transient
receptor potential vanilloid-1 in human prostate
carcinoma. J Cancer Res Clin Oncol 2009; 135: 507–
14.
86 Chung SC, Hammarsten P, Josefsson A, et al. A high
cannabinoid CB(1) receptor immunoreactivity is
associated with disease severity and outcome in
prostate cancer. Eur J Cancer 2009; 45: 174–82.
87 Thors L, Bergh A, Persson E, et al. Fatty acid amide
hydrolase in prostate cancer: association with disease
severity and outcome, CB1 receptor expression and
regulation by IL-4. PLoS One 2010; 5: e12275.
88 Piñeiro R, Maffucci T, Falasca M. The putative
cannabinoid receptor GPR55 defines a novel autocrine
loop in cancer cell proliferation. Oncogene 2011; 30:
142–52.
89 Hohmann AG, Guindon J. The endocannabinoid
system and cancer: therapeutic implication. Br J
Pharmacol 2011; 163: 1447–63.
90 Díaz-Laviada I. The endocannabinoid system in
prostate cancer. Nat Rev Urol 2011; 8: 553–61.
91 Orellana-Serradell O, Poblete CE, Sanchez C, et al.
Proapoptotic effect of endocannabinoids in prostate
cancer cells. Oncol Rep 2015; 33: 1599–608.
92 Agostinis P, Berg K, Cengel K, et al. Photodynamic
Therapy of Cancer: an Update. CA Cancer J Clin
2011; 61: 250–81.
93 Allison RR, Moghissi K. Oncologic photodynamic
therapy: Clinical strategies that modulate mechanisms
of action. Photodiagnosis Photodyn Ther 2013; 10:
331–41.
94 Benov L. Photodynamic Therapy: Current Status and
Future Directions. Med Princ Pract 2015; 24: 14–28.
95 Wang W, Moriyama LT, Bagnato VS. Photodynamic
therapy induced vascular damage: an overview of
experimental PDT. Laser Phys Lett 2013; 10: 23001.
96 Kushibiki T, Hirasawa T, Okawa S, Ishihara M.
Responses of cancer cells induced by photodynamic
therapy. J Healthc Eng 2013; 4: 87–108.
97 Anand S, Ortel BJ, Pereira SP, Hasan T, Maytin E V.
Biomodulatory approaches to photodynamic therapy
for solid tumors. Cancer Lett 2012; 326: 8–16.
98 Weijer R, Broekgaarden M, Kos M, et al. Enhancing
photodynamic therapy of refractory solid cancers:
combining second-generation photosensitizers with
multi-targeted liposomal delivery. J Photochem
Photobiol C Photochem Rev 2015; 23: 103–31.
99 Lamberti MJ. Breast cancer as photodynamic therapy
@Real Academia Nacional de Farmacia. Spain
target: Enhanced therapeutic efficiency by overview
of tumor complexity. World J Clin Oncol 2014; 5:
901.
100 Rogers L, Sergeeva NN, Paszko E, Vaz GMF, Senge
MO. Lead Structures for Applications in
Photodynamic Therapy. 6. Temoporfin Anti-
Inflammatory Conjugates to Target the Tumor
Microenvironment for In Vitro PDT. PLoS One 2015;
10: e0125372.
101 Tomanová P, Rimpelová S, Jurášek M, et al.
Trilobolide–porphyrin conjugates: On synthesis and
biological effects evaluation. Steroids 2015; 97: 8–12.
102 Trivedi ER, Blumenfeld CM, Wielgos T, et al. Multi-
gram synthesis of a porphyrazine platform for cellular
translocation, conjugation to Doxorubicin, and cellular
uptake. Tetrahedron Lett 2012; 53: 5475–78.
103 Zhang S, Jia N, Shao P, Tong Q, Xie X-Q, Bai M.
Target-selective phototherapy using a ligand-based
photosensitizer for type 2 cannabinoid receptor. Chem
Biol 2014; 21: 338–44.
104 Morales P, Moreno L, Fernández-ruiz J, Jagerovic N.
Synthesis of a novel CB2 cannabinoid-porphyrin
conjugate based on an antitumor
chromenopyrazoledione. J Porphyr Phthalocyanines
2017; 21: 67–76.
105 Sawzdargo M, Nguyen T, Lee DK, et al. Identification
and cloning of three novel human G protein-coupled
receptor genes GPR52, PsiGPR53 and GPR55:
GPR55 is extensively expressed in human brain. Brain
Res Mol Brain Res 1999; 64: 193–8.
106 Ryberg E, Larsson N, Sjögren S, Hjorth S,
Hermansson N-O, Leonova J et al. The orphan
receptor GPR55 is a novel cannabinoid receptor. Br J
Pharmacol 2007; 152: 1092–101.
107 Morales P, Jagerovic N. Advances towards the
Discovery of GPR55 Ligands. Curr Med Chem 2016;
23: 2087–100.
108 Ross RA. The enigmatic pharmacology of GPR55.
Trends Pharmacol Sci 2009; 30: 156–63.
109 Console-Bram L, Ciuciu SM, Zhao P, Zipkin RE,
Brailoiu E, Abood ME. N-arachidonoyl glycine,
another endogenous agonist of GPR55. Biochem
Biophys Res Commun 2017; 490: 1389-93.
110 Heynen-genel S, Dahl R, Shi S, et al. Screening for
Selective Ligands for GPR55-Antagonists. Probe
Reports from the NIH Molecular Libraries Program;
National Center for Biotechnology Information (U.S.):
Bethesda, MD, 2010; http://www.ncbi.nlm.nih.
gov/books/NBK66153/. nih. .
111 Yrjölä S, Parkkari T, Navia-Paldanius D, et al. Potent
and selective N-(4-sulfamoylphenyl)thiourea-based
GPR55 agonists. Eur J Med Chem 2016; 107: 119–32.
112 Morales P, Whyte LS, Chicharro R, et al.
Identification of Novel GPR55 Modulators Using
Cell-Impedance-Based Label-Free Technology. J Med
Chem 2016; 58: 1840-53.
183